Professor Xiaojun Huang ‘s Team Reveals New Mechanism of Injury to Bone Marrow Endothelial Progenitor Cells and Proposes Targeted Repair Strategies

Professor Xiaojun Huang ‘s Team Reveals New Mechanism of Injury to Bone Marrow Endothelial Progenitor Cells and Proposes Targeted Repair Strategies

2024.01.10
🩸 Professor Xiaojun Huang and Team: Illuminating Hope in Blood Health Meet the unsung heroes—Professor Xiaojun Huang and their dedicated team—who've ventured into the labyrinth of blood health, uncovering a profound truth within our marrow's tapestry. They've unraveled a poignant narrative—a disruption in glycolysis, a hidden force causing turmoil for endothelial progenitor cells (EPCs). This upheaval imperils the delicate dance of hematopoiesis, the heartbeat of our blood's resilience. Backed by national R&D programs and the unwavering support of the National Natural Science Foundation, their discovery isn't just science; it's a lifeline for those navigating the storm of chemotherapy, radiotherapy, and stem cell transplants. Picture the impact—precision treatments targeting this anomaly, preserving the marrow's sanctity amid the chaos of treatments, kindling hope for countless souls. Their tale echoed at prestigious gatherings—the 24th European Hematology Association Congress (EHA) and the 48th European Society for Blood and Marrow Transplantation Congress (EBMT)—etched in Haematologica journal's pages.
Dr. Massimo Federico: 10-Year Follow-up Results of Early FDG-PET Adaptive Treatment for Limited-Stage HL

Dr. Massimo Federico: 10-Year Follow-up Results of Early FDG-PET Adaptive Treatment for Limited-Stage HL

2024.01.08
At the International Malignant Lymphoma Conference (ICML 2023), Dr. Massimo Federico from University of Modena and Reggio Emilia, presented a captivating report on 10-Year Follow-up Analysis of the EORTC/LYSA/FIL H10 Randomized Intergroup Trial during the "Focus on Hodgkin Lymphoma" session. Oncology Frontier specially invited Dr. Federico for an in-depth interview on this topic.
ASH 2023丨Professor Lin Tongyu: Decoding ASH Conference Insights on Lymphoma Treatment, Potential Revealed in r/r-PTCL with EZH1/2 Inhibitor HH2853

ASH 2023丨Professor Lin Tongyu: Decoding ASH Conference Insights on Lymphoma Treatment, Potential Revealed in r/r-PTCL with EZH1/2 Inhibitor HH2853

2024.01.05
From December 9 to 12, the highly anticipated 65th American Society of Hematology (ASH) Annual Meeting took place in San Diego, USA. Focused on the annual pinnacle in the field of hematologic malignancies, the front-line reporting team of "Oncology Insights" delved into the forefront, witnessing the outstanding performance of "China's Good Voice" on the international stage. In the realm of aggressive lymphomas, advancements in targeted and cellular immunotherapy continue to dominate. To comprehensively grasp the lymphoma treatment developments at this ASH conference, "Oncology Insights" had the privilege of interviewing Professor Lin Tongyu from Sun Yat-sen University Cancer Hospital, who provided insightful analysis on the topic.
ASH Exclusive Interview | Professor Junmin Li: Addition of Homoharringtonine Improves Induction Therapy Efficacy in Low to Intermediate-Risk AML Patients with Chemotherapy Insensitivity

ASH Exclusive Interview | Professor Junmin Li: Addition of Homoharringtonine Improves Induction Therapy Efficacy in Low to Intermediate-Risk AML Patients with Chemotherapy Insensitivity

2024.01.05
Acute myeloid leukemia (AML) is a highly heterogeneous group with varying sensitivities to chemotherapy. The "7+3" regimen has been the standard induction chemotherapy for AML for 50 years. In the era of precision medicine, optimizing induction therapy for AML is a crucial issue. At the recent 65th American Society of Hematology (ASH) Annual Meeting, Professor Junmin Li's team from the Hematology Department of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, presented the initial results of the RJ-AML2016 study. This multicenter, randomized, Phase III trial investigated the efficacy of adding Homoharringtonine (HHT) to optimize the idarubicin and cytarabine induction regimen based on Day 5 Peripheral Blast Clearance Rate (D5-PBCR) in newly diagnosed young AML patients. "Hematology Frontier" had the privilege of interviewing Professor Li on the study's key findings and the team's next research plans.
ASH Big Shot Interview | Professor Jie Jin : IL1RAP-TCE Antibody Effectively Eliminates Leukemia Stem Cells in AML

ASH Big Shot Interview | Professor Jie Jin : IL1RAP-TCE Antibody Effectively Eliminates Leukemia Stem Cells in AML

2024.01.05
From December 9 to 12, 2023, the 65th American Society of Hematology (ASH) Annual Meeting was grandly held in San Diego, USA, in a hybrid format combining online and offline sessions. As one of the largest and most comprehensive international academic conferences in the field of hematology, experts and scholars from around the world gathered to explore the latest frontiers in hematologic diseases, new treatment methods and strategies, and disease management approaches. At this year's ASH Annual Meeting, Professor Jin Jie and her team from the First Affiliated Hospital of Zhejiang University School of Medicine presented an oral report titled "IL1RAP-Specific T Cell Engager (TCE) Antibody Effectively Clears Leukemia Stem Cells (LSC) in Acute Myeloid Leukemia (AML)." "Tumor Watch" had the privilege of interviewing Professor Jin Jie on-site to discuss the research and its related content.
ASH China Voice | Prof. Huang Huiqiang: Final Follow-up Report on the Combined Treatment of Relapsed/Refractory Extranodal NK/T-Cell Lymphoma with Pembrolizumab and Sintilimab (SCENT)

ASH China Voice | Prof. Huang Huiqiang: Final Follow-up Report on the Combined Treatment of Relapsed/Refractory Extranodal NK/T-Cell Lymphoma with Pembrolizumab and Sintilimab (SCENT)

2024.01.05
From December 9 to December 12, 2023, the 65th American Society of Hematology Annual Meeting (ASH) took place in San Diego. Experts from around the world in the field of hematologic malignancies gathered, presenting a wealth of exciting content. During this conference, Professor Huang Huiqiang and his team from Sun Yat-sen University Cancer Center reported the long-term follow-up results of their phase Ib/II clinical study on the use of immune checkpoint inhibitor (PD-1) in combination with sintilimab for the treatment of relapsed/refractory extranodal NK/T-cell lymphoma. At the ASH conference, "Oncology Insight" had the privilege of inviting Prof. Huang Huiqiang to provide insights into this groundbreaking research.
ASH 2023 | Prof. Fengkui Zhang and Prof. Bing Han Team: KP104 Effectively Controls Intravascular and Extravascular Hemolysis in PNH Patients Without Complement Inhibitor Treatment

ASH 2023 | Prof. Fengkui Zhang and Prof. Bing Han Team: KP104 Effectively Controls Intravascular and Extravascular Hemolysis in PNH Patients Without Complement Inhibitor Treatment

2024.01.05
Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare and life-threatening blood disorder. Due to the complexity of complement biology and various pathogenic pathways, there remains a significant unmet clinical need, urgently requiring next-generation drugs with superior efficacy and dosing convenience compared to current therapies. At the recently held 65th American Society of Hematology (ASH) Annual Meeting, Prof. Fengkui Zhang from the Hematology Hospital of the Chinese Academy of Medical Sciences (Institute of Hematology) and Prof. Bing Han's team from Peking Union Medical College Hospital presented an oral report (Abstract: 572). The study explored the safety and effectiveness of the dual-function C5 antibody/H factor fusion protein KP104 in PNH patients who had not received complement inhibitor treatment. This research brings hope to address this challenging issue and has been selected as a highlight of "ASH 2024." The summarized details are presented below in this issue of "Hematology Insight."
ASH 2023丨Professor Chunrui Li: Outstanding Efficacy of Idecabtagene Vicleucel (CT103A) in the Treatment of Refractory/Relapsed Multiple Myeloma

ASH 2023丨Professor Chunrui Li: Outstanding Efficacy of Idecabtagene Vicleucel (CT103A) in the Treatment of Refractory/Relapsed Multiple Myeloma

2024.01.05
In the just-concluded 65th American Society of Hematology (ASH) Annual Meeting, CAR-T therapy emerged as a crucial advancement in the treatment of Multiple Myeloma (MM). The only approved BCMA CAR-T in China, Idecabtagene Vicleucel (CT103A), shone brightly. Professor Chunrui Li and her team from Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, presented a study (abstract 761) reporting the efficacy and safety data of CT103A in refractory/relapsed MM, garnering widespread attention. "Tumor Insights" had the privilege of interviewing Professor Li at the event, delving deep into the advancements in MM treatment and future directions